EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials

Maryatun Hasan, Kurnia F. Jamil, Darmawi Darmawi, Maimun Syukri, Muhammad Alif Naufal

Asian Pacific Journal of Tropical Medicine · 2026-08 · 19 (8) · 335-343

DOI: 10.4103/apjtm.apjtm_735_25 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Asian Pacific Journal of Tropical Medicine, online erschienen am 29.07.2026. Verfasst von Maryatun Hasan und 4 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effect of statin therapy on biomarkers of vascular inflammation in people living with HIV (PLWH).

Methods

We conducted a living systematic review of randomized controlled trials (RCTs). We searched Scopus, PubMed, Cochrane Library, and Scilit up to April 4, 2025, with a predefined plan for ongoing evidence surveillance and updating. Nine RCTs involving 1 721 participants were included. Data were extracted on changes in key biomarkers, including interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble CD14 (sCD14), soluble CD163 (sCD163), oxidized LDL (oxLDL), and lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ). The Cochrane Risk of Bias (RoB 2) tool was used for quality assessment. This review is not intended to be retired from the living mode at this stage.

Results

Statin therapy significantly reduced key biomarkers of monocyte activation and vascular inflammation, particularly IL-6 and sCD14, with effects being most consistent and pronounced with pitavastatin. Pitavastatin also demonstrated greater efficacy in reducing oxLDL and Lp-PLA 2 compared to other statins. Reductions in hs-CRP were inconsistent across studies. A critical finding was that treatment duration was a major modifier of effect, with interventions lasting ≥12 months yielding substantially greater anti-inflammatory benefits. The mechanistic profile suggests statins specifically target the LPS-sCD14 pathway of innate immune activation, which is highly relevant to HIV pathogenesis.

Conclusions

Pitavastatin emerges as the most effective statin for reducing vascular inflammation in PLWH, offering a targeted strategy to mitigate cardiovascular disease risk in this population. These findings, derived from the current iteration of a living systematic review, support the use of long-term pitavastatin therapy for PLWH with evidence of residual inflammation and highlight the need for its inclusion in future clinical guidelines as new evidence continues to emerge.

Zitieren

APA

Hasan, M., Jamil, K. F., Darmawi, D., Syukri, M., & Naufal, M. A. (2026). The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials. Asian Pacific Journal of Tropical Medicine, 19(8), 335-343. https://doi.org/10.4103/apjtm.apjtm_735_25

Vancouver

Hasan M, Jamil KF, Darmawi D, Syukri M, Naufal MA. The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials. Asian Pacific Journal of Tropical Medicine. 2026;19(8):335-343. doi:10.4103/apjtm.apjtm_735_25

BibTeX
@article{Hasan2026,
  author = {Hasan, Maryatun and Jamil, Kurnia F. and Darmawi, Darmawi and Syukri, Maimun and Naufal, Muhammad Alif},
  title = {The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials},
  journal = {Asian Pacific Journal of Tropical Medicine},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {335--343},
  doi = {10.4103/apjtm.apjtm_735_25}
}
Kostenlos starten →